Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PAX3 | P23760 | 1/20 | 0.37 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.37 |
| ▸ | HINT1 | P49773 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479239 | 1.00 | KDM4E (0.52) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 | |
| SCHEMBL7251830 | 0.89 | KDM4E (0.56) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 | |
| SCHEMBL38653234 | 0.86 | KDM4E (0.57) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 | |
| SCHEMBL29138074 | 0.83 | KDM4E (0.58) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 | |
| SCHEMBL14853853 | 0.83 | ADORA3 (0.51) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 | |
| SCHEMBL14946251 | 0.83 | ADORA3 (0.51) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 | |
| SCHEMBL29973022 | 0.81 | KDM4E (0.46) | KDM4EADORA2ATAS1R3TAS1R1POLA1 | |
| SCHEMBL24049587 | 0.81 | KDM4E (0.57) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 | |
| SCHEMBL24049319 | 0.81 | KDM4E (0.57) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 | |
| SCHEMBL25589113 | 0.81 | KDM4E (0.57) | KDM4EADORA2ATAS1R3TAS1R1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024153127-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20240059729-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-02-22 | — | — | US | disclosed |
| EP-4242218-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022083584-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059729-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | MAVS, IRF3, STING1 | KDM4E 2917/4885ADORA2A 599/4885TAS1R3 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.